Low-molecular-weight heparin: The optimal duration of prophylaxis against postoperative venous thromboembolism after total hip or knee replacement

Thrombosis Research

Volumn 101, Issue 1, 2001, Pages 163-173

  Heit, J A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Low molecular weight heparin; Venous thromboembolism

Indexed keywords

LOW MOLECULAR WEIGHT HEPARIN;

COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; HUMAN; KNEE ARTHROPLASTY; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SUDDEN DEATH; SURVIVAL; THROMBOEMBOLISM; TOTAL HIP PROSTHESIS;

EID: 0035122239     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0049-3848(00)00388-1     Document Type: Review

References (36)

1. Trends in the incidence of deep vein thrombosis and pulmonary embolism: A 25-year population-based study
2. Predictors of survival after deep vein thrombosis and pulmonary embolism
3. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worchester DVT study
4. Incidence of idiopathic deep venous thrombosis and secondary thromboembolism among ethnic groups in California
5. Risk factors for deep vein thrombosis and pulmonary embolism: A population-based case-control study
6. Epidemiological observations of thromboembolic disease during pregnancy and in the puerperium in 56,022 women
7. Epidemiology of oral contraceptives and cardiovascular disease
8. Postmenopausal hormone therapy increased risk for venous thromboembolic disease
9. Prevention of venous thromboembolism
10. Incidence of posthospitalization proximal deep venous thrombosis after total hip arthroplasty. A pilot study
11. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: Double-blind randomized comparison of enoxaparin versus placebo
12. Prolonged thromboprophylaxis following hip replacement surgery - Results of a double-blind, prospective, randomized, placebo-controlled study with dalteparin (Fragmin)
13. Low-molecular-weight heparin prophylaxis using dalteparin extended out of hospital versus warfarin/out-of-hospital placebo in hip arthroplasty patients
14. Clinical outcome of orthopaedic patients with negative lower limb venography at discharge
15. Post discharge clinically overt venous thromboembolism in orthopaedic surgery patients with negative venography - An overview analysis
16. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement
17. Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty - The Danish Prolonged Prophylaxis (DaPP) Study
18. A double-blind multicenter clinical trial comparing long term enoxaparin and placebo treatments in the prevention of venous thromboembolic disease after hip and knee replacement surgery
19. A double-blind multicenter clinical trial comparing long term enoxaparin and placebo treatments in the prevention of venous thromboembolic disease after hip and knee replacement surgery
20. Venous thromboembolism associated with hip and knee arthroplasty: Current prophylactic practices and outcomes
21. The efficacy of prophylaxis with low-dose warfarin for prevention of pulmonary embolism following total hip arthroplasty
22. Ultrasonographic screening before hospital discharge for deep venous thrombosis after arthroplasty: The post-arthroplasty screening study. A randomized, controlled trial
23. Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty. Evaluation during hospitalization and three months after discharge
24. The incidence of symptomatic venous thromboembolism during and after prophylaxis with enoxaparin: A multi-institutional cohort study in patients who underwent hip or knee arthroplasty
25. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty
26. Ardeparin sodium for extended out-of-hospital prophylaxis against venous thromboembolism after total hip or knee replacement. A randomized, double-blind, placebo-controlled trial
27. Postphlebitic syndrome after hip arthroplasty
28. Clinical course and incidence of post-thrombophlebitic syndrome after profound asymptomatic deep vein thrombosis. Results of a transverse epidemiologic study
29. Postthrombotic syndrome after hip or knee arthroplasty: A cross-sectional study
30. Long-term clinical observations and venous functional abnormalities after asymptomatic venous thrombosis following total hip or knee arthroplasty
31. Does total hip arthroplasty predispose to chronic venous insufficiency?
32. Late deep venous thrombosis and delayed weightbearing after total hip arthroplasty
33. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis
34. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal vein thrombosis
35. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism
36. APC-resistance is a risk factor for postoperative thromboembolism in elective replacement of the hip or knee; a prospective study